Literature DB >> 11934545

Use of positron emission tomography for the assessment of skeletal muscle glucose metabolism.

Oliver Selberg1, Manfred James Müller, Jörg van den Hoff, Wolfgang Burchert.   

Abstract

Positron emission tomography (PET) is a unique tool for studying regional skeletal muscle glucose metabolism and blood flow in vivo. The application of PET in the assessment of skeletal muscle glucose metabolism depends on recent improvements in instrumentation, data analysis, and production of (18)F-fluorodeoxyglucose (FDG) and (15)O water. The data presented support the validity of the (15)O water model to measure blood flow and the FDG model for the determination of glucose uptake and glucose kinetic constants (influx, efflux, and phosphorylation) in skeletal muscle. However, quantification of absolute glucose transport and backflux rates should be applied with caution because those calculations are based on unproven assumptions such as validity of the lumped constant for these individual processes and constancy of the free and accessible intracellular glucose pool. It is evident that quantification of glucose fluxes using the triple tracer technology generates conflicting data that violate assumptions inherent in triple tracer or PET modeling. Further FDG-PET studies will have to solve those problems to provide more insight into the regulatory processes of glucose transport and phosphorylation of different insulin-resistant disease states. Promising new areas of PET research will include not only detailed study of glucose kinetics but also the measurement of muscle protein synthesis in vivo, which is of interest in a variety of conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934545     DOI: 10.1016/s0899-9007(01)00799-7

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  7 in total

Review 1.  Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.

Authors:  Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

2.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

3.  A positron emission tomography approach to visualize flow perfusion in hollow-fiber membrane bioreactors.

Authors:  Davod Mohebbi-Kalhori
Journal:  J Artif Organs       Date:  2011-07-15       Impact factor: 1.731

4.  Regional Variation in Skeletal Muscle and Adipose Tissue FDG Uptake Using PET/CT and Their Relation to BMI.

Authors:  Marcus D Goncalves; Judith Green-McKenzie; Abass Alavi; Drew A Torigian
Journal:  Acad Radiol       Date:  2017-05-24       Impact factor: 3.173

5.  Metabolic activity of the tongue in obstructive sleep apnea. A novel application of FDG positron emission tomography imaging.

Authors:  Andrew M Kim; Brendan T Keenan; Nicholas Jackson; Eugenia L Chan; Bethany Staley; Drew A Torigian; Abass Alavi; Richard J Schwab
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

6.  18F-fluorodeoxyglucose and PET/CT for noninvasive study of exercise-induced glucose uptake in rat skeletal muscle and tendon.

Authors:  Dorthe Skovgaard; Michael Kjaer; Henrik El-Ali; Andreas Kjaer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-10       Impact factor: 9.236

7.  FDG uptake tracks the oxidative damage in diabetic skeletal muscle: An experimental study.

Authors:  Matteo Bauckneht; Vanessa Cossu; Patrizia Castellani; Patrizia Piccioli; Anna Maria Orengo; Laura Emionite; Francesco Di Giulio; Maria Isabella Donegani; Alberto Miceli; Stefano Raffa; Anna Borra; Selene Capitanio; Silvia Morbelli; Giacomo Caviglia; Silvia Bruno; Silvia Ravera; Davide Maggi; Gianmario Sambuceti; Cecilia Marini
Journal:  Mol Metab       Date:  2019-11-15       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.